In this week's Pharma Pulse, the EU Council adopts the "pharma package," Commerce details 0% tariffs for certain drugs and Sharp expands autoinjector assembly capacity.
News|Articles|August 3, 2026
FAQ: Pharma's July 31 Tariff Deadline Has Passed. Now What?
Author(s)Stephen Appezzato
The Section 232 tariff deadline for 17 major drugmakers has arrived. Here's what pharma supply chain teams need to know now.
Advertisement
Advertisement
The Section 232 pharmaceutical tariff regime is no longer a future date on the calendar. As of July 31, 2026, it's active law for the industry's largest manufacturers, with a second deadline and a separate generics timeline still ahead. Here's what changed and what to watch next.
Related to this article
In this week's Pharma Pulse, PhRMA sues to block CMS's GLOBE pricing model, WFS opens a temperature-controlled cargo terminal in Lyon and Bayer commits $2.2 billion to a new Ohio manufacturing site.
Episode 3 of Supply Chain Signal examines the Aug. 31 MFN agreements with nine mid-size manufacturers, the GENEROUS Medicaid model and whether pricing, trade and manufacturing policy now add up to a new pharma operating model.
Zoomlogi's Henry Ames explains how AI agents are resolving supply chain exceptions, from unlinked IoT trackers to after-hours escalation calls.
Aeropowder will begin U.S. production of its recycled-feather PluumoPlus insulation in Q1 2027 through a manufacturing deal with ColdCorr.
As organized groups add impersonation and email fraud to hijackings and trailer thefts, every handoff between shipping partners has become a point of exposure.
Octapharma USA's Kerem Tokel explains how product value and supply risk should shape freight security, and why complacency remains a persistent gap.
At LogiPharma USA 2026, Cold Chain Technologies' TJ Rizzo explains how gaps in end-to-end cold chain expertise create risk for advanced therapies.
Advertisement
Advertisement